Computer tool aims to personalize colon cancer screening for the uninsured
NCT ID NCT03705897
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests a computerized tool that collects patient information and generates personalized, guideline-based next steps for colorectal cancer screening. It focuses on a large, diverse population of under- and uninsured patients in Dallas. The goal is to improve screening rates and reduce over- or under-screening.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a computerized risk stratification tool that collects patient data and generates personalized screening recommendations
- What this could lead to
- If successful, this approach could help ensure that more people get the right colorectal cancer screening at the right time, potentially reducing cancer deaths.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new drug or therapy. The tool's impact on actual cancer outcomes remains to be seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
9,264 people
The number who actually took part.
- Start date
-
Aug 2013
- Finished
-
Dec 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients, ages 25-64, presenting for appointment will be eligible to participate. * Patients 25-49 must also have family hx of CRC or personal hx of inflammatory bowel disease or adenomatous polyps. * No racial or ethnic group will be excluded from participation. * Both English and Spanish speakers will be eligible for participation. Exclusion Criteria: * Patients with a personal history of CRC are not eligible to participate. * Patients who do not speak Spanish or English or have severely impaired hearing or speech or do not give informed consent will also be excluded from participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?